Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor Patients

NCT04973527 is registered in ClinicalTrials.gov with Beijing Boren Hospital as lead sponsor.

NCT NCT04973527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04973527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor Patients
Lead sponsor
Beijing Boren Hospital
Phase
Phase 1
Overall status
Terminated
Start date
July 2, 2021
Completion date
July 20, 2022
Enrollment
9 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

t cell lymphoma, t-cell leukemia